Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

192 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-01

Study Completion Date

2027-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial aims to evaluate the effect of temporary methotrexate (MTX) discontinuation on the humoral immunogenicity of the 20-valent pneumococcal conjugate vaccine (PCV20) in adult patients with autoimmune rheumatic diseases (ARDs).

Key questions:

* Does suspending MTX for 2 weeks after PCV20 enhance humoral immunogenicity?
* What is the impact of MTX discontinuation on functional opsonophagocytic activity (OPA) and cellular immunity?
* What is the risk of disease flaring with MTX withdrawal?

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases

NCT07252791

Autoimmune Rheumatologic Disease

NOT_YET_RECRUITING PHASE4

A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

NCT02097264

Inflammation Rheumatoid Arthritis

WITHDRAWN PHASE2

Effect of MTX Discontinuation on Shingrix Response in RA

NCT06574594

Rheumatoid Arthritis

RECRUITING NA

A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy

NCT03001219

Rheumatoid Arthritis

TERMINATED PHASE2

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

NCT01636843

Inflammation Rheumatoid Arthritis

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with autoimmune rheumatic diseases (ARDs) have an increased risk of infections, including invasive pneumococcal disease, due to underlying immune dysregulation and the frequent use of immunosuppressive therapies. Pneumococcal vaccination is strongly recommended in this population; however, methotrexate (MTX), a cornerstone therapy for ARDs, has been consistently associated with reduced vaccine immunogenicity.

Evidence from randomized clinical trials in influenza and COVID-19 vaccination has demonstrated that short-term MTX discontinuation (10-14 days post-vaccination) can significantly enhance humoral immune responses. However, this strategy may be accompanied by an increased risk of mild disease flare. Importantly, no study to date has evaluated the effect of temporary MTX discontinuation on pneumococcal vaccination, representing a critical knowledge gap in the care of immunosuppressed patients.

The 20-valent pneumococcal conjugate vaccine (PCV20) represents the most comprehensive pneumococcal conjugate vaccine currently licensed, covering 20 serotypes responsible for the majority of invasive disease. Unlike polysaccharide vaccines, conjugate vaccines generate T-cell dependent immune responses, leading to higher-quality and longer-lasting protection. Yet, the immunogenicity of PCV20 in patients with ARDs under MTX therapy has not been investigated.

This randomized, double-blind, controlled clinical trial will evaluate the impact of a 2-week MTX discontinuation following PCV20 vaccination in patients with ARDs in remission or low disease activity. A total of 192 adult patients will be enrolled and randomized 1:1 to either suspend MTX for 2 weeks after vaccination or continue MTX treatment as usual.

All participants will receive one dose of PCV20 at baseline (D0). Blood samples will be collected at baseline (D0), 4 weeks post-vaccination (D28), and 12 months post-vaccination (D180). Humoral immunogenicity will be assessed by quantifying IgG antibody concentrations against 12 vaccine serotypes using multiplex Luminex assays. In addition, we will evaluate serotype-specific opsonophagocytic activity (OPA) assays to assess functional antibody responses.

Disease activity will be monitored throughout the study using standardized indices (DAS28 for rheumatoid arthritis, ASDAS for spondyloarthritis, SLEDAI for systemic lupus erythematosus, MMT for myopathies, among others).

Safety assessments will include the recording of local and systemic adverse events in structured diaries and surveillance for disease flares, with predefined management protocols.

The primary endpoint is the seroconversion rate at 4 weeks after PCV20, defined as at least a twofold increase in IgG antibody levels for ≥50% of included serotypes.

Secondary endpoints include persistence of humoral immunity at 6 months, OPA titers, disease flare rates and adverse events.

By directly addressing the effect of MTX on PCV20 immunogenicity and incorporating both functional and cellular immune measures, this trial will generate critical evidence to guide vaccination strategies in immunosuppressed patients with ARDs and has the potential to inform future international guidelines.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autoimmune Rheumatic Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MTX suspension

Participants randomized to this arm will receive one dose of the 20-valent pneumococcal conjugate vaccine (PCV20) at baseline (D0). They will be instructed to discontinue methotrexate (MTX) for 2 weeks following vaccination, then resume their regular MTX regimen. Prednisone up to 5 mg/day and other stable background therapies will be maintained. Blood samples will be collected at baseline (D0), 4 weeks post-vaccination (D28), and 6 months post-vaccination (D180).

Group Type EXPERIMENTAL

Pneumococcal Vaccine

Intervention Type BIOLOGICAL

All participants will receive a single intramuscular dose (0.5 mL) of PCV20 (Prevnar 20®, Pfizer), administered into the deltoid muscle at baseline (Day 0). PCV20 contains purified capsular polysaccharides of 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F), individually conjugated to the nontoxic diphtheria CRM197 carrier protein. The conjugation induces a T-cell dependent immune response, resulting in higher-affinity antibodies and immune memory compared to polysaccharide vaccines.

MTX

Participants randomized to this arm will receive one dose of the 20-valent pneumococcal conjugate vaccine (PCV20) at baseline (D0). They will continue MTX therapy without interruption during the vaccination period, maintaining their stable immunosuppressive regimen. Prednisone up to 5 mg/day and other stable background therapies will also be maintained. Blood samples will be collected at baseline (D0), 4 weeks post-vaccination (D28), and 6 months post-vaccination (D180).

Group Type ACTIVE_COMPARATOR

Pneumococcal Vaccine

Intervention Type BIOLOGICAL

All participants will receive a single intramuscular dose (0.5 mL) of PCV20 (Prevnar 20®, Pfizer), administered into the deltoid muscle at baseline (Day 0). PCV20 contains purified capsular polysaccharides of 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F), individually conjugated to the nontoxic diphtheria CRM197 carrier protein. The conjugation induces a T-cell dependent immune response, resulting in higher-affinity antibodies and immune memory compared to polysaccharide vaccines.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pneumococcal Vaccine

All participants will receive a single intramuscular dose (0.5 mL) of PCV20 (Prevnar 20®, Pfizer), administered into the deltoid muscle at baseline (Day 0). PCV20 contains purified capsular polysaccharides of 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F), individually conjugated to the nontoxic diphtheria CRM197 carrier protein. The conjugation induces a T-cell dependent immune response, resulting in higher-affinity antibodies and immune memory compared to polysaccharide vaccines.

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

20-valent Pneumococcal Conjugate Vaccine (PCV20)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults (\>=18 years ) with confirmed ARD diagnosis (e.g., RA, PsA, axial SpA, primary Sjögren's, SLE, IIM, SSc, MCTD).
* Stable MTX dose ≥12 weeks.
* Prednisone ≤5 mg/day.
* Low disease activity/remission according to specific disease activity criteria.
* Eligible for PCV20 vaccination (no prior PCV20).

Exclusion Criteria

* Anaphylaxis to vaccine components.
* Acute febrile illness.
* Guillain-Barré, decompensated CHF (NYHA III-IV), demyelinating disease.
* Live vaccine ≤4 weeks or inactivated vaccine ≤2 weeks before.
* Blood products in last 6 months.
* Severe infection in last month (including pneumococcal).
* Hospitalization at enrollment.
* Refusal to participate or inability to complete study procedures.

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No